Skip to content

The clinical efficacy and safety of oblique lateral interbody fusion and transforaminal interbody fusion in the treatment of degenerative lumbar spondylolisthesis: a randomized controlled trial

The clinical efficacy of OLIF in the treatment of lumbar degeneration

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068763
Enrollment
Unknown
Registered
2023-02-28
Start date
2023-02-20
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative lumbar spondylolisthesis

Interventions

OLIF group:Oblique lateral interbody fusion
TLIF group:Transforaminal interbody fusion

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? The clinical manifestation is acute or chronic low back pain with or without intermittent claudication. The symptoms obviously affect daily work and life, and cannot be relieved after 6 months of strict non-surgical treatment. ? X-rays, CT or MRI showed single-level degenerative lumbar spondylolisthesis (L2/3-L4/5), and Mild symptomatic degenerative lumbar spondylolisthesis (Meyerding Grade I or II). ? Age >18 years old. ? X-ray of lumbar dynamic position shows that there is intervertebral instability at the responsible segment. ? No obvious operation contraindication. ? The patient agreed and voluntarily joined the clinical trial.

Exclusion criteria

Exclusion criteria: ? Spinal deformity (rotational deformity, scoliosis). ? Lumbar tumor, infection, lumbar fracture, etc. ? Severe osteoporosis. ? Bony lumbar spinal stenosis. ? A previous lumbar spinal surgery history. ? Huge intervertebral disc herniation, annulus fibrosus rupture and nucleus pulposus prolapse at the lesion segment.

Design outcomes

Primary

MeasureTime frame
VAS score;ODI score;operation time;intraoperative blood loss;postoperative drainage;postoperative hospital stay;complications;

Secondary

MeasureTime frame
lumbar lordosis (LL);fused segment lordosis;intervertebral space height (ISH);Intervertebral foramen height (IFH);fusion rate;

Countries

China

Contacts

Public ContactWeiqiang Liu

Weifang People's Hospital

liuwqspine@126.com18765109800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026